Clinical trials: Temozolomide, completed
Brain and Central Nervous System Tumors
Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00033280
- Testing
- temozolomide, neoadjuvant therapy, radiation therapy
- Where
- 39 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- Radiation Therapy Oncology Group
Glioblastoma, Glioblastoma Multiforme
Phase I EGFR BATs in Newly Diagnosed Glioblastoma
This is a phase I trial using EGFR Bi-armed Activated T-cells (BATs) in combination with standard of care temozolomide (TMZ) and radiation (RT) in patients with glioblastoma (GBM).
- Trial name
- NCT03344250
- Testing
- EGFR BATs with TMZ following SOC RT/TMZ, Weekly EGFR BATs following SOC RT/TMZ
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Virginia
Primary Central Nervous System Lymphoma
Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System
Primary central nervous system lymphomas are rare aggressive malignancies, usually treated in two steps: an induction phase (where a combination of chemotherapy is given) followed by a consolidation phase (where patients usually…
- Trial name
- FIORELLA (NCT03495960)
- Testing
- Rituximab, Methotrexate, Procarbazine
- Where
- 34 sites in Denmark, Finland and 2 more
- Volunteers
- 72 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Unspecified Adult Solid Tumor, Protocol Specific
Docetaxel and Temozolomide in Treating Patients With Metastatic Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00401180
- Testing
- docetaxel, temozolomide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- The Cleveland Clinic
Brain and Central Nervous System Tumors
HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM
This phase II trial studies the side effects and how well HSPPC-96 (vitespen) and temozolomide work in treating patients with newly diagnosed glioblastoma multiforme.
- Trial name
- HeatShock (NCT00905060)
- Testing
- HSPPC-96, Temozolomide, Standard Surgical Resection
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- University of California, San Francisco
Glioblastoma
Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma
RATIONALE: Drugs used in chemotherapy, such as Gliadel wafer and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01310868
- Testing
- 5-ALA, Gliadel wafers, Radiotherapy as normal based on standard clinical protocols determined by the neuro-oncologist
- Where
- 10 sites in United Kingdom
- Volunteers
- 59 people
- Sponsor
- University College, London
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors
RATIONALE: Talabostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide and carboplatin, work in different ways to stop the growth of tumor…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Kidney Cancer, Liver Cancer
- Trial name
- NCT00303940
- Testing
- carboplatin, talabostat mesylate, temozolomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
High Risk WHO Grade II Glioma, Recurrent/Post-Chemotherapy WHO Grade II Glioma
Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas
This is a pilot study of a vaccination regime that is designed to efficiently induce anti-tumor T-cell responses in patients with WHO grade II glioma.
- Trial name
- NCT01678352
- Testing
- Tumor Lysate Vaccine, Imiquimod
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Frank Lieberman
Adult Brain Glioblastoma, Adult Giant Cell Glioblastoma
Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
This phase 1 trial studies the side effects and best dose of dimethyl fumarate when given together with temozolomide and radiation therapy(RT) in treating patients with newly diagnosed glioblastoma multiforme (GBM).
- Conditions
- Adult Brain Glioblastoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT02337426
- Testing
- Dimethyl Fumarate, Temozolomide, Radiation Therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Virginia Commonwealth University
Colorectal Cancer
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer
This is a Phase II, non-randomized, open-label study to evaluate temozolomide in combination with olaparib in patients with MGMT promoter hypermethylated advanced colorectal cancer.
- Trial name
- NCT04166435
- Testing
- Temozolomide + Olaparib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Yale University
Glioblastoma
Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.
The purpose of this study is to show if prolonging treatment with temozolomide to 12 cycles improve progression-free survival in patients with glioblastoma included in this study, randomized according to…
- Trial name
- NCT02209948
- Testing
- Temozolomide
- Where
- 20 sites in Spain
- Volunteers
- 166 people
- Sponsor
- Grupo Español de Investigación en Neurooncología
Brain Metastases, Radiotherapy
FSRT Combined With TMZ for Large BMs: a PSM Study
A propensity- matched study was conducted to investigate the feasibility and safety of adding temozolomide to hypofractionated stereotactic radiotherapy for large brain metastases.
- Conditions
- Brain Metastases, Radiotherapy, Chemotherapy
- Trial name
- NCT03338075
- Testing
- fractionated stereotactic radiotherapy
- Volunteers
- 72 people
- Sponsor
- Chinese Academy of Medical Sciences
Brain and Central Nervous System Tumors
Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00387400
- Testing
- everolimus, temozolomide, microarray analysis
- Where
- 9 sites in Canada
- Volunteers
- 32 people
- Sponsor
- NCIC Clinical Trials Group
Lung Diseases, Cancer
Combination Paclitaxel, Carboplatin and Temozolomide
The purpose of this study is to determine the maximum tolerable dose of temozolomide in combination with fixed dose of paclitaxel and carboplatin and to determine the overall tumor response rate with this combination and to…
- Trial name
- NCT00249964
- Testing
- Combination Treatment - Cohort 1, Combination Treatment - Cohort 2, Combination Treatment - Cohort 3
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- New Mexico Cancer Research Alliance
Gliosarcoma, Newly Diagnosed
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Background: Glioblastoma is a type of brain cancer. Treatments include radiation, chemotherapy, and surgery. But survival rates are poor.
- Conditions
- Gliosarcoma, Newly Diagnosed, Glioblastoma
- Trial name
- NCT04216329
- Testing
- Selinexor, Temozolomide, Generic Radiation therapy (RT)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Central Nervous System Neoplasm
Temozolomide in Treating Patients With Recurrent High-Grade Glioma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00619112
- Testing
- temozolomide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, San Francisco
Neuroendocrine Carcinoma
Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)
To study the efficacy of everolimus combined with temozolomide as first-line treatment in advanced gastroenteropancreatic neuroendocrine carcinoma with a Ki67 of 20-55%, measured as disease control rate (non-progressive disease)…
- Trial name
- NCT02248012
- Testing
- Everolimus , temozolomide
- Where
- Norway
- Volunteers
- 38 people
- Sponsor
- Haukeland University Hospital
Acoustic Schwannoma, Adult Anaplastic (Malignant) Meningioma
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
This phase I trial studies the side effects and best dose of gamma-secretase/Notch signalling pathway inhibitor RO4929097 (RO4929097) when given together with temozolomide and radiation therapy in treating patients with newly…
- Conditions
- Acoustic Schwannoma, Adult Anaplastic (Malignant) Meningioma, Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
- Trial name
- NCT01119599
- Testing
- 3-Dimensional Conformal Radiation Therapy, Gamma-Secretase Inhibitor RO4929097, Intensity-Modulated Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastomas
Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable Glioblastoma
In the last 20 years, only temozolomide has obtained indication for the treatment of High-grade glioma (HGG). Temozolomide during and later radiation therapy has doubled one year survival and is the standard treatment for…
- Trial name
- NCT01102595
- Testing
- Temozolomide, Bevacizumab, Standard radiation therapy
- Where
- Spain
- Volunteers
- 102 people
- Sponsor
- Grupo Español de Investigación en Neurooncología
Glioblastoma
PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs
PTK is an investigational new drug that has been shown in early laboratory studies to prevent the formation of new blood vessels that allow the tumor to grow.
- Trial name
- NCT00385853
- Testing
- PTK787/ZK 222584, Temozolomide, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Massachusetts General Hospital